S-1: Change Agents Corp. Files for Stock Resale

Change Agents Corporation (CHGA) has filed a registration statement for the resale of up to 35,569,258 shares of common stock by selling stockholders.

Summary

• Change Agents Corporation (formerly Avalon GloboCare Corp.) has filed a registration statement (Form S-1) for the resale of up to 35,569,258 shares of its common stock by various selling stockholders.
• The company is a technology-focused entity with operations in AI software (Avalon Quantum AI, LLC) and consumer health products (Keto Air breathalyzer).
• The filing details a significant history of net losses and an accumulated deficit, raising substantial doubt about the company's ability to continue as a going concern.
• Recent financing activities include issuances of convertible preferred stock and promissory notes, alongside a business loan.
• The company has recently expanded its strategic focus to include AI-enabled autonomous drone surveillance and counter-unmanned aerial systems (C-UAS) through a new subsidiary, Autonomous Air Defense LLC.
• The company is also actively seeking complementary AI acquisitions to supplement its current operations.
• The filing highlights the company's ongoing efforts to manage its financial position, including a recent name change and Nasdaq ticker symbol change.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the company's ongoing financial struggles, significant net losses, and substantial doubt about its ability to continue as a going concern, despite strategic pivots and new ventures.

Positives

• The company is actively pursuing growth in the AI sector with its Catch-Up AI-powered Video Platform and Beacon Agentic GEO search product.
• Expansion into the defense technology sector with the formation of Autonomous Air Defense LLC.
• The Keto Air breathalyzer device is FDA registered and offers a non-invasive method for ketosis measurement.
• The company is actively seeking strategic AI acquisitions to bolster its revenue and operations.
• Recent financing activities, including the issuance of Series F Convertible Preferred Stock and a business loan, provide some capital infusion.
• The company has a new CFO, Sam Knipper, and a new Chief Strategy Officer, Luisa Ingargiola, indicating potential for fresh strategic direction.

Negatives

• The company has a history of net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• As of July 31, 2026, the company had approximately $200,000 in cash, sufficient for only one month of operations, requiring $5,000,000 for 12 months of operations.
• Outstanding indebtedness as of July 31, 2026, was approximately $2.1 million.
• The company has not generated sustainable revenue since inception and anticipates it will take approximately one year to generate meaningful revenue from its Catch-Up platform.
• The company received a deficiency notice from Nasdaq regarding its minimum bid price, with a deadline of October 12, 2026, to regain compliance.
• Significant related party transactions, including the sale of property to a director, raise concerns about potential conflicts of interest and corporate governance.
• The company has a limited operating history in its current business segments, making future prospects difficult to evaluate.

Risks

• The company has a limited operating history in its current business segments, making it difficult to evaluate its business and future prospects.
• The company has a history of net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The company does not currently have enough cash to support operations for the next 12 months.
• The company has outstanding indebtedness that could adversely affect its financial condition and liquidity.
• The company may not be successful in commercializing its AI platform or its Keto Air product.
• The company faces intense competition in both of its business segments, with many competitors having substantially greater resources.
• The company's business is subject to rapid technological change, and failure to adapt could negatively impact its operations.
• The use of AI in the company's platform may give rise to legal liability, reputational harm, and regulatory scrutiny.

Future Outlook

The company is focused on developing and commercializing its AI software and consumer health products, while also exploring strategic acquisitions and expansion into defense technology. However, its ability to continue operations is heavily dependent on securing additional financing due to its current cash position and history of losses.

Management Comments

• We believe our diverse and evolving portfolio of commercial activities reflects our ongoing commitment to identifying and building value-oriented technology businesses for the benefit of its stockholders.
• We are actively seeking complementary bolt-on AI acquisitions that could generate near-term revenue to supplement our current operations as both segments continue to develop.

Industry Context

StockSavvy.ai notes that the company's pivot towards AI, particularly generative AI and agentic AI, aligns with significant industry trends. The expansion into drone surveillance and C-UAS technologies also taps into a growing market driven by defense and security needs. However, the competitive landscape in AI is intense, with many established players and startups vying for market share.

Comparison to Industry Standards

• The company's net losses and negative cash flow from operations are common among early-stage technology companies, but the scale of these losses and the limited cash runway are concerning.
• While many AI companies are experiencing rapid growth, Change Agents Corporation has yet to demonstrate significant revenue generation from its core AI products, which lags behind industry leaders.
• The company's reliance on equity financing and debt, coupled with a low stock price, places it in a challenging position compared to better-capitalized competitors in the AI and defense technology sectors.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in a lawsuit filed by Research Institute at Nationwide Childrens Hospital concerning misappropriation of trade secrets, with a settlement agreement in place involving future profit-sharing payments.

Related Party Transactions

• Sale of 100% of the membership interests of Avalon RT 9 Properties, LLC to Wenzhao Lu (Chairman of the Board) for approximately $9,000,000.
• Consulting services provided by Wilbert Tauzin (former director) and his son.
• Exchange of Series A Preferred Stock for Series D Preferred Stock between the company and Wenzhao Lu.
• Michael Mathews, a director, received Series E Preferred Stock as part of the RPM acquisition consideration.

Stakeholder Impact

• Shareholders may experience dilution due to potential future sales of common stock under the ELOC Purchase Agreement and exercise of warrants.
• The company's financial instability and potential delisting could negatively impact shareholder value.
• Employees and contractors may be affected by the company's ongoing financial challenges and need for capital.

Next Steps

• The company intends to seek stockholder approval for the issuance of shares underlying the ELOC Warrant within 75 calendar days of the purchase agreement date.
• Phase 2 development of the Catch-Up platform is expected to launch in Q3 2026.
• The company will continue to evaluate possible AI acquisitions.
• The company must regain compliance with Nasdaq's minimum bid price requirement by October 12, 2026.

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial net losses, an accumulated deficit, and a critical cash shortage, raising serious going concern issues. The reliance on future financing, potential Nasdaq delisting, and the history of unfulfilled strategic initiatives outweigh the potential positives of its AI and defense technology ventures. Investors should exercise extreme caution.

Keywords

AI software, Agentic AI, video generation, consumer health, breathalyzer, ketosis, drone surveillance, defense technology